{"id":35976,"date":"2023-10-26T09:51:56","date_gmt":"2023-10-26T09:51:56","guid":{"rendered":"https:\/\/prosfunds.com\/investing\/biogen-and-eisai-release-new-alzheimers-drug-data-that-may-support-wider-uptake\/"},"modified":"2023-10-26T09:51:57","modified_gmt":"2023-10-26T09:51:57","slug":"biogen-and-eisai-release-new-alzheimers-drug-data-that-may-support-wider-uptake","status":"publish","type":"post","link":"https:\/\/prosfunds.com\/?p=35976","title":{"rendered":"Biogen and Eisai release new Alzheimer\u2019s drug data that may support wider uptake"},"content":{"rendered":"
\n

Biogen Inc. and Eisai Co. late Wednesday released new data on their Alzheimer\u2019s treatment Leqembi that may ultimately help bolster uptake of the drug.<\/p>\n

Weekly treatment with an experimental subcutaneous formulation of Leqembi, which could be easier to administer than the currently approved biweekly intravenous version, resulted in 14% greater amyloid-plaque removal than the IV treatment after six months, the companies said in a release. Amyloid plaques, a hallmark of Alzheimer\u2019s disease, are protein clumps that can accumulate in the brain and disrupt neurons. <\/p>\n

\n

Data on the experimental form of Leqembi have been highly anticipated by investors. The U.S. Food and Drug Administration\u2019s full approval of intravenous Leqembi in July didn\u2019t give Biogen shares
\n BIIB,
\n -2.14%<\/bg-quote>
\n much of a boost, as analysts predicted a slow rollout in part because of the U.S. health system\u2019s limited capacity to administer the biweekly infusions. A subcutaneous option could alleviate any infusion bottlenecks and prove more convenient for patients and caregivers, analysts said. <\/p>\n

Looking at Leqembi uptake in late September, Jefferies analysts called it \u201ca little wave right now, but not a swell.\u201d After a slower start, the launch may gather steam by the second half of next year, the analysts wrote. <\/p>\n

Rates of a potentially serious Leqembi side effect associated with brain swelling were similar between the subcutaneous and IV versions, Biogen and Eisai
\n ESALF,
\n -0.72%<\/bg-quote>
\n said Wednesday. The data were presented at this week\u2019s Clinical Trials on Alzheimer\u2019s Disease conference in Boston. <\/p>\n

Eisai said that it plans to apply for U.S. regulatory approval of the subcutaneous form of Leqembi by the end of March 2024. Eli Lilly & Co.\u2019s
\n LLY,
\n -1.01%<\/bg-quote>
\n experimental Alzheimer\u2019s treatment donanemab, which like Leqembi has been found to slow the progression of the disease, could get FDA approval by the end of this year. <\/p>\n

Biogen shares fell 2.1% Wednesday and have dropped 10.9% in the year to date , while Eisai shares fell 0.7% Wednesday and are down 16.1% in the year to date. <\/p>\n<\/p><\/div>\n<\/div>\n

Read the full article here<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Biogen Inc. and Eisai Co. late Wednesday released new data on their Alzheimer\u2019s treatment Leqembi that may ultimately help bolster uptake of the drug. Weekly treatment with an experimental subcutaneous formulation of Leqembi, which could be easier to administer than the currently approved biweekly intravenous version, resulted in 14% greater amyloid-plaque removal than the IV […]<\/p>\n","protected":false},"author":1,"featured_media":35977,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"content-type":"","footnotes":""},"categories":[32],"tags":[],"class_list":{"0":"post-35976","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-investing"},"yoast_head":"\nBiogen and Eisai release new Alzheimer\u2019s drug data that may support wider uptake | Prosfunds<\/title>\n<meta name=\"description\" content=\"Biogen Inc. and Eisai Co. late Wednesday released new data on their Alzheimer\u2019s treatment Leqembi that may ultimately help bolster uptake of the drug.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/prosfunds.com\/?p=35976\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biogen and Eisai release new Alzheimer\u2019s drug data that may support wider uptake | Prosfunds\" \/>\n<meta property=\"og:description\" content=\"Biogen Inc. and Eisai Co. late Wednesday released new data on their Alzheimer\u2019s treatment Leqembi that may ultimately help bolster uptake of the drug.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/prosfunds.com\/?p=35976\" \/>\n<meta property=\"og:site_name\" content=\"Prosfunds\" \/>\n<meta property=\"article:published_time\" content=\"2023-10-26T09:51:56+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-10-26T09:51:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/prosfunds.com\/wp-content\/uploads\/2023\/10\/1698313916_social.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1279\" \/>\n\t<meta property=\"og:image:height\" content=\"640\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"News Room\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"News Room\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/prosfunds.com\/?p=35976#article\",\"isPartOf\":{\"@id\":\"https:\/\/prosfunds.com\/?p=35976\"},\"author\":{\"name\":\"News Room\",\"@id\":\"https:\/\/prosfunds.com\/#\/schema\/person\/bab8f1b00ccebe43e39ff640793108e6\"},\"headline\":\"Biogen and Eisai release new Alzheimer\u2019s drug data that may support wider uptake\",\"datePublished\":\"2023-10-26T09:51:56+00:00\",\"dateModified\":\"2023-10-26T09:51:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/prosfunds.com\/?p=35976\"},\"wordCount\":350,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/prosfunds.com\/#organization\"},\"articleSection\":[\"Investing\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/prosfunds.com\/?p=35976#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/prosfunds.com\/?p=35976\",\"url\":\"https:\/\/prosfunds.com\/?p=35976\",\"name\":\"Biogen and Eisai release new Alzheimer\u2019s drug data that may support wider uptake | Prosfunds\",\"isPartOf\":{\"@id\":\"https:\/\/prosfunds.com\/#website\"},\"datePublished\":\"2023-10-26T09:51:56+00:00\",\"dateModified\":\"2023-10-26T09:51:57+00:00\",\"description\":\"Biogen Inc. and Eisai Co. late Wednesday released new data on their Alzheimer\u2019s treatment Leqembi that may ultimately help bolster uptake of the drug.\",\"breadcrumb\":{\"@id\":\"https:\/\/prosfunds.com\/?p=35976#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/prosfunds.com\/?p=35976\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/prosfunds.com\/?p=35976#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/prosfunds.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biogen and Eisai release new Alzheimer\u2019s drug data that may support wider uptake\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/prosfunds.com\/#website\",\"url\":\"https:\/\/prosfunds.com\/\",\"name\":\"Funding Factories\",\"description\":\"Latest Finance News and Updates\",\"publisher\":{\"@id\":\"https:\/\/prosfunds.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/prosfunds.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/prosfunds.com\/#organization\",\"name\":\"Funding Factories\",\"url\":\"https:\/\/prosfunds.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/prosfunds.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/prosfunds.com\/wp-content\/uploads\/2023\/08\/ff-dark-logo-1.png\",\"contentUrl\":\"https:\/\/prosfunds.com\/wp-content\/uploads\/2023\/08\/ff-dark-logo-1.png\",\"width\":780,\"height\":140,\"caption\":\"Funding Factories\"},\"image\":{\"@id\":\"https:\/\/prosfunds.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/prosfunds.com\/#\/schema\/person\/bab8f1b00ccebe43e39ff640793108e6\",\"name\":\"News Room\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/prosfunds.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/prosfunds.com\/wp-content\/uploads\/2023\/08\/avatar_user_1_1693518183-96x96.png\",\"contentUrl\":\"https:\/\/prosfunds.com\/wp-content\/uploads\/2023\/08\/avatar_user_1_1693518183-96x96.png\",\"caption\":\"News Room\"},\"sameAs\":[\"https:\/\/prosfunds.com\"],\"url\":\"https:\/\/prosfunds.com\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Biogen and Eisai release new Alzheimer\u2019s drug data that may support wider uptake | Prosfunds","description":"Biogen Inc. and Eisai Co. late Wednesday released new data on their Alzheimer\u2019s treatment Leqembi that may ultimately help bolster uptake of the drug.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/prosfunds.com\/?p=35976","og_locale":"en_US","og_type":"article","og_title":"Biogen and Eisai release new Alzheimer\u2019s drug data that may support wider uptake | Prosfunds","og_description":"Biogen Inc. and Eisai Co. late Wednesday released new data on their Alzheimer\u2019s treatment Leqembi that may ultimately help bolster uptake of the drug.","og_url":"https:\/\/prosfunds.com\/?p=35976","og_site_name":"Prosfunds","article_published_time":"2023-10-26T09:51:56+00:00","article_modified_time":"2023-10-26T09:51:57+00:00","og_image":[{"width":1279,"height":640,"url":"https:\/\/prosfunds.com\/wp-content\/uploads\/2023\/10\/1698313916_social.jpeg","type":"image\/jpeg"}],"author":"News Room","twitter_card":"summary_large_image","twitter_misc":{"Written by":"News Room","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/prosfunds.com\/?p=35976#article","isPartOf":{"@id":"https:\/\/prosfunds.com\/?p=35976"},"author":{"name":"News Room","@id":"https:\/\/prosfunds.com\/#\/schema\/person\/bab8f1b00ccebe43e39ff640793108e6"},"headline":"Biogen and Eisai release new Alzheimer\u2019s drug data that may support wider uptake","datePublished":"2023-10-26T09:51:56+00:00","dateModified":"2023-10-26T09:51:57+00:00","mainEntityOfPage":{"@id":"https:\/\/prosfunds.com\/?p=35976"},"wordCount":350,"commentCount":0,"publisher":{"@id":"https:\/\/prosfunds.com\/#organization"},"articleSection":["Investing"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/prosfunds.com\/?p=35976#respond"]}]},{"@type":"WebPage","@id":"https:\/\/prosfunds.com\/?p=35976","url":"https:\/\/prosfunds.com\/?p=35976","name":"Biogen and Eisai release new Alzheimer\u2019s drug data that may support wider uptake | Prosfunds","isPartOf":{"@id":"https:\/\/prosfunds.com\/#website"},"datePublished":"2023-10-26T09:51:56+00:00","dateModified":"2023-10-26T09:51:57+00:00","description":"Biogen Inc. and Eisai Co. late Wednesday released new data on their Alzheimer\u2019s treatment Leqembi that may ultimately help bolster uptake of the drug.","breadcrumb":{"@id":"https:\/\/prosfunds.com\/?p=35976#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/prosfunds.com\/?p=35976"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/prosfunds.com\/?p=35976#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/prosfunds.com\/"},{"@type":"ListItem","position":2,"name":"Biogen and Eisai release new Alzheimer\u2019s drug data that may support wider uptake"}]},{"@type":"WebSite","@id":"https:\/\/prosfunds.com\/#website","url":"https:\/\/prosfunds.com\/","name":"Funding Factories","description":"Latest Finance News and Updates","publisher":{"@id":"https:\/\/prosfunds.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/prosfunds.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/prosfunds.com\/#organization","name":"Funding Factories","url":"https:\/\/prosfunds.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/prosfunds.com\/#\/schema\/logo\/image\/","url":"https:\/\/prosfunds.com\/wp-content\/uploads\/2023\/08\/ff-dark-logo-1.png","contentUrl":"https:\/\/prosfunds.com\/wp-content\/uploads\/2023\/08\/ff-dark-logo-1.png","width":780,"height":140,"caption":"Funding Factories"},"image":{"@id":"https:\/\/prosfunds.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/prosfunds.com\/#\/schema\/person\/bab8f1b00ccebe43e39ff640793108e6","name":"News Room","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/prosfunds.com\/#\/schema\/person\/image\/","url":"https:\/\/prosfunds.com\/wp-content\/uploads\/2023\/08\/avatar_user_1_1693518183-96x96.png","contentUrl":"https:\/\/prosfunds.com\/wp-content\/uploads\/2023\/08\/avatar_user_1_1693518183-96x96.png","caption":"News Room"},"sameAs":["https:\/\/prosfunds.com"],"url":"https:\/\/prosfunds.com\/?author=1"}]}},"_links":{"self":[{"href":"https:\/\/prosfunds.com\/index.php?rest_route=\/wp\/v2\/posts\/35976","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/prosfunds.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/prosfunds.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/prosfunds.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/prosfunds.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=35976"}],"version-history":[{"count":1,"href":"https:\/\/prosfunds.com\/index.php?rest_route=\/wp\/v2\/posts\/35976\/revisions"}],"predecessor-version":[{"id":35978,"href":"https:\/\/prosfunds.com\/index.php?rest_route=\/wp\/v2\/posts\/35976\/revisions\/35978"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/prosfunds.com\/index.php?rest_route=\/wp\/v2\/media\/35977"}],"wp:attachment":[{"href":"https:\/\/prosfunds.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=35976"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/prosfunds.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=35976"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/prosfunds.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=35976"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}